Float Short %

33.98

Margin Of Safety %

Put/Call OI Ratio

0.57

EPS Next Q Diff

1.25

EPS Last/This Y

3.38

EPS This/Next Y

-1.89

Price

7.62

Target Price

12.78

Analyst Recom

2.5

Performance Q

-17.35

Relative Volume

1.1

Beta

2.58

Ticker: NVAX

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	NVAX	6.66	0.64	0.16	303937
2025-12-10	NVAX	6.74	0.64	0.14	305798
2025-12-11	NVAX	6.69	0.63	0.18	306658
2025-12-12	NVAX	6.57	0.63	0.07	306996
2025-12-15	NVAX	6.59	0.64	0.09	300260
2025-12-16	NVAX	6.55	0.63	2.49	303011
2025-12-17	NVAX	6.53	0.63	0.07	308975
2025-12-18	NVAX	6.68	0.63	0.07	309585
2025-12-19	NVAX	6.67	0.63	0.06	310100
2025-12-22	NVAX	6.89	0.63	0.05	300463
2025-12-23	NVAX	6.8	0.61	0.03	306207
2025-12-26	NVAX	6.82	0.59	0.12	309329
2025-12-29	NVAX	6.82	0.62	0.04	299972
2025-12-30	NVAX	6.71	0.59	0.02	301298
2025-12-31	NVAX	6.73	0.58	0.05	303279
2026-01-02	NVAX	7.14	0.57	0.28	305419
2026-01-05	NVAX	7.25	0.58	0.01	301627
2026-01-06	NVAX	7.43	0.58	0.03	301452
2026-01-07	NVAX	7.61	0.57	0.05	306394
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	NVAX	6.66	-5.6	-	2.15
2025-12-10	NVAX	6.74	-5.6	-	2.15
2025-12-11	NVAX	6.69	-5.6	-	2.15
2025-12-12	NVAX	6.57	-5.6	-	2.15
2025-12-15	NVAX	6.58	-5.6	-	2.15
2025-12-16	NVAX	6.58	-5.6	-	2.15
2025-12-17	NVAX	6.54	-5.6	-	2.15
2025-12-18	NVAX	6.69	-5.6	-	2.15
2025-12-19	NVAX	6.67	-5.6	-	2.15
2025-12-22	NVAX	6.91	-5.6	-	2.15
2025-12-23	NVAX	6.78	-5.6	-	2.15
2025-12-26	NVAX	6.82	-5.6	-	2.15
2025-12-29	NVAX	6.83	-5.6	-	2.15
2025-12-30	NVAX	6.72	-5.6	-	2.15
2025-12-31	NVAX	6.72	-5.6	-	2.15
2026-01-02	NVAX	7.13	-5.6	-	2.15
2026-01-05	NVAX	7.26	-5.6	-	2.15
2026-01-06	NVAX	7.43	-5.6	-	2.15
2026-01-07	NVAX	7.62	-5.6	-	2.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	NVAX	0.00	0.63	34.17
2025-12-10	NVAX	0.00	0.63	34.97
2025-12-11	NVAX	0.00	0.63	34.97
2025-12-12	NVAX	0.00	0.63	34.97
2025-12-15	NVAX	0.00	0.63	33.50
2025-12-16	NVAX	0.00	0.63	33.50
2025-12-17	NVAX	0.00	0.63	33.50
2025-12-18	NVAX	0.00	0.63	33.50
2025-12-19	NVAX	0.00	0.63	33.50
2025-12-22	NVAX	0.00	0.62	33.50
2025-12-23	NVAX	0.00	0.62	33.50
2025-12-26	NVAX	0.00	0.62	33.98
2025-12-29	NVAX	0.00	0.62	33.98
2025-12-30	NVAX	0.00	0.62	33.98
2025-12-31	NVAX	0.00	0.62	33.98
2026-01-02	NVAX	0.00	0.62	33.98
2026-01-05	NVAX	0.00	0.63	33.98
2026-01-06	NVAX	0.00	0.63	33.98
2026-01-07	NVAX	0.00	0.63	33.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-1.25

Avg. EPS Est. Current Quarter

-0.49

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

0.63

Beta

2.58

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

114

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

97.7

Max Drawdown 5-Year %

-98.8

Target Price

12.78

P/E

4.31

Forward P/E

59.37

PEG

0.94

P/S

1.16

P/B

P/Free Cash Flow

EPS

1.77

Average EPS Est. Cur. Y

2.15

EPS Next Y. (Est.)

0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

32.1

Relative Volume

1.1

Return on Equity vs Sector %

-245.2

Return on Equity vs Industry %

-230.1

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Novavax, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 952

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

stock quote shares NVAX – Novavax, Inc. Stock Price stock today

news today NVAX – Novavax, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch NVAX – Novavax, Inc. yahoo finance google finance

stock history NVAX – Novavax, Inc. invest stock market

stock prices NVAX premarket after hours

ticker NVAX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: NVAX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y